PLB1004 waxaa lagu dari lahaa daaweynta degdegga ah

PLB1004, oo ay soo saartay Beijing Avistone Biotechnology Co., Ltd., waa dawo badbaado leh, aad loo xushay, oo waxtar leh oo aan dib loo celin karin oo soo-dhoweeyaha koritaanka epidermal-ka ee tyrosine kinase inhibitor (EGFR-TKI) oo loo isticmaalo daaweynta kansarka sambabada ee unugyada yar yar (NSCLC).

Abriil 9, 2025, Xarunta Qiimaynta Dawooyinka ee Maamulka Badeecadaha Caafimaadka Qaranka (CDE) waxay muujisay in PLB1004 ee Beijing Avistone Biotechnology loogu talagalay in lagu daro daaweynta degdegga ah ee bukaanada qaba kansarka sambabada ee unugyada yaryar ee aan ahayn METastatic (NSCLC) ee ku dhacay isbeddelka EGFR, la kulmay ballaarin iyo/ama muujinta xad dhaafka ah ka dib markii lagu guuldareystay daaweynta EGFR-TKI.

Natiijooyinka caafimaad ee hordhaca ah ee PLB1004 oo lagu daray Vebreltinib ee daaweynta bukaanada kansarka sambabada ee unugyada yaryar ee qaba isbeddellada EGFR, kordhinta MET ama muujinta xad-dhaafka ah ee MET ka dib EGFR-TKI ayaa lagu dhawaaqay Shirka Adduunka ee Kansarka Sambabada ee 2024.

Afartan iyo afar bukaan ayaa la siiyay Vebreltinib 100mg oo lagu daray PLB1004 160mg (n=15), Vebreltinib 150mg oo lagu daray PLB1004 160mg (n=13), Vebreltinib 200mg oo lagu daray PLB1004 80mg (n=3), ama Vebreltinib 150mg oo lagu daray PLB1004 80mg (n=13) waxaana lagu daray falanqaynta guud ee badbaadada. 44-ta bukaan ee la qiimeeyay, 36.4% bukaannada ayaa qabay metastases maskaxda ah halka 86.4% bukaannada ay hore u heleen EGFR-TKI jiil saddexaad, siday u kala horreeyaan. Jawaabaha ujeeddada ah ayaa ka dhacay dhammaan heerarka qiyaasta Vebreltinib iyo PLB1004 ee la baaray, iyadoo jawaab celin qayb ah (PRs) lagu arkay 19/32 (59.4%) bukaannada lagu qiimeeyo jawaab celinta. Bukaannada qaba metastases maskaxda, ORR wuxuu ahaa 75.0% (9/12). ORR wuxuu ahaa 58.6% (17/29) bukaannada qaatay EGFR-TKI-gii hore ee jiilka saddexaad. TRAE-yada ugu badan waxay ahaayeen finan iyo paronychia. Bukaanna ma joojin daaweynta TRAEs awgood.

Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.

Lambarka Taleefanka: 4008803716

Email：myimmnet@163.com